FDA Approves Enfortumab Vedotin Ejfv, Pembrolizumab Duo

1. Blog Detail Home | Blog | Blog Detail Impomed Healthcare Mar 17,2024 FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer UPDATE: 04/24, NEW APPROVAL BY US-FDA   On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic urothelial cancer (la/mUC). FDA previously granted accelerated approval to this combination for patients with la/mUC who are ineligible for cisplatin-containing chemotherapy.   Full prescribing information for Padcev and Keytruda will be posted here. Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API Printed with Pdfcrowd.com

2.     Efficacy was evaluated in EV-302/KN-A39 (NCT04223856), an open-label, randomized trial of 886 patients with la/mUC and no prior systemic therapy for advanced disease. Patients were randomized 1:1 to receive either enfortumab vedotin-ejfv with pembrolizumab (gemcitabine with either cisplatin or carboplatin). Randomization was stratified by cisplatin eligibility, PD-L1 expression, and presence of liver metastases. The major efficacy outcome measures were overall survival (OS) and progression-free survival (PFS) as assessed by blinded independent central review. Statistically significant improvements in both OS and PFS were demonstrated for enfortumab vedotin-ejfv with pembrolizumab compared with platinum- based chemotherapy. Median OS was 31.5 months (95% CI: 25.4, not estimable) for patients who received enfortumab vedotin-ejfv with pembrolizumab and 16.1 months (95% CI: 13.9, 18.3) for those who received platinum-based chemotherapy (Hazard ratio [HR] 0.47 [95% CI: 0.38, 0.58]; p value<0.0001). Median PFS was 12.5 months (95% CI: 10.4, 16.6) for patients who received enfortumab vedotin ejfv with pembrolizumab and 6.3 months (95% CI: 6.2, 6.5) for those who received platinum-based chemotherapy (HR 0.45 [95% CI: 0.38, 0.54]; p-value<0.0001).   The most common (≥20%) adverse abnormalities, in patients receiving pembrolizumab were increased aspartate aminotransferase, increased creatinine, rash, increased glucose, peripheral neuropathy, increased lipase, decreased lymphocytes, increased alanine aminotransferase, decreased hemoglobin, fatigue, decreased sodium, decreased phosphate, decreased albumin, pruritus, diarrhea, alopecia, decreased weight, decreased appetite, increased urate, decreased neutrophils, decreased potassium, dry eye, nausea, constipation, increased potassium, dysgeusia, urinary tract infection, and decreased platelets.    The recommended enfortumab vedotin-ejfv pembrolizumab is 1.25 mg/kg (up to a maximum of 125 mg for patients ≥ 100 kg) or platinum-based chemotherapy reactions, enfortumab including vedotin-ejfv laboratory with dose when given with Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API Printed with Pdfcrowd.com

3. administered as an intravenous infusion over 30 minutes on Days 1 and 8 of a 21 day cycle until disease progression or unacceptable toxicity.  The recommended pembrolizumab dose when given withenfortumab vedotin- ejfv is 200 mgadministered as an intravenous infusion every 3 weeks or 400 mg every 6 weeks until disease progression, unacceptable toxicity, or two years of therapy. This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration and Health Canada.  This review used the Real-Time Oncology Review pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application 5 months ahead of the FDA goal date.   This application was granted priority review and breakthrough designation. FDA expedited programs are described in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics.      DISCLAIMER:  ➢ Information shared here is solely based on the data available on web and intended for general awareness of HCPs.   ➢ ImpoMed Healthcare Pvt Ltd. New Delhi, is in no way associated with the product/s development or claims.     Copyright © 2024 ImpoMed Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API Printed with Pdfcrowd.com